Hypersensitivity reaction to intravenous but not oral tacrolimus.

@article{Nicolai2012HypersensitivityRT,
  title={Hypersensitivity reaction to intravenous but not oral tacrolimus.},
  author={Sarah Nicolai and Supinda Bunyavanich},
  journal={Transplantation},
  year={2012},
  volume={94 9},
  pages={
          e61-3
        }
}
Overcoming drug hypersensitivity reactions can improve transplant patient care, especially when specific medications are integral to treatment protocols. Our allergy service was consulted on a 40-year-old female hematopoietic stem cell transplantation (HSCT) patient for a hypersensitivity reaction during intravenous (IV) tacrolimus infusion. The patient was recently diagnosed with AML M5a and was status-post induction chemotherapy in her first complete remission. She was admitted for a… 
Successful switch to oral tacrolimus in a patient with hypersensitivity reaction to parenteral vitamin K, cyclosporine, and tacrolimus: A case report
TLDR
It appears that Cremophor EL (polyoxyethylated castor oil) which acts as a carrier, solubilizer, and emulsifier in intravenous calcineurin inhibitors is responsible for the occurrence of anaphylactic reaction (anaphylaxis); therefore, it is suggested that the administration of cremophor-containing drug should be avoided in patients with a previous history of hypersensitivity reaction to one of these drugs.
Intravenous tacrolimus and cyclosporine induced anaphylaxis: what is next?
TLDR
A case of anaphylaxis caused by vitamin K (phytonadine), serotonin antagonist (granisetron), intravenous tacrolimus, and cyclosporine is reported, and the patient tolerated oral cyclospora, which did not contain Cremophor EL or polysorbate 80.
Rectal and sublingual administration of tacrolimus: a single-dose pharmacokinetic study in healthy volunteers.
TLDR
Sublingual administration of a single dose of tacrolimus does not result in systemic exposure if care is taken not to swallow saliva and to rinse the oral cavity afterwards, and rectal administration results in clinically relevant systemic exposure and might represent an alternative formulation in case oral administration is not feasible.
A Pediatric Patient with Intravenous Cyclosporine Anaphylaxis Who Tolerated the Oral Form
  • P. Işık, N. Özbek, B. Tunç
  • Medicine
    Turkish journal of haematology : official journal of Turkish Society of Haematology
  • 2014
Pamir Işık1, Namik Özbek1, Emine Dibek Mısırlıoğlu2, Turan Bayhan3, Suna Emir1, Fatih Mehmet Azık1, Bahattin Tunç1 1Ankara Children’s Hematology and Oncology Education and Research Hospital, Clinic
Mitigation of Tacrolimus-Associated Nephrotoxicity by PLGA Nanoparticulate Delivery Following Multiple Dosing to Mice while Maintaining its Immunosuppressive Activity
TLDR
Findings show a potential for PLGA NPs in reducing the nephrotoxicity of TAC while preserving the immunosuppressive activity and significantly lower drug-associated toxicity with an activity comparable to Prograf for TAC-loaded PLGANPs.
Development and characterization of methoxy poly(ethylene oxide)-block-poly(ε-caprolactone) (PEO-b-PCL) micelles as vehicles for the solubilization and delivery of tacrolimus
...
...

References

SHOWING 1-8 OF 8 REFERENCES
Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine: case report and review.
  • G. Volcheck, R. G. van Dellen
  • Medicine
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 1998
Intravenous cyclosporine and tacrolimus caused anaphylaxis but oral cyclosporine capsules were tolerated in an allogeneic bone marrow transplant recipient
TLDR
Oral capsule of Sandimmun is a safe alternative to prevent GVHD in such a case of anaphylactic reaction against intravenous formulation in a Japanese female patient with angioimmunoblastic T cell lymphoma.
IgE-mediated anaphylaxis after first intravenous infusion of cyclosporine.
  • D. Ebo, G. Piel, V. Conraads, W. Stevens
  • Medicine
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2001
Abraxane for the Treatment of Gynecologic Cancer Patients With Severe Hypersensitivity Reactions to Paclitaxel
TLDR
Abraxane is well tolerated in women with gynecologic cancer who have experienced a paclitaxel-associated hypersensitivity reaction, and further studies are ongoing to determine the clinical activity of Abraxane in the treatment of these malignancies.
The effects of cremophor EL in the anaesthetized dog
TLDR
The effects of cremophor EL were studied in 13 anaesthetized, paralyzed and ventilated dogs and this model could be used in studying anaphylactoid reactions and their prevention and treatment.
Evaluated the patient and edited the manuscript. Supported by K08AI09353801 from the National Institutes of Health